HSPPC-96: Clinical Trials

8 trials of HSPPC-96, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 terminated, 1 unknown, 1 withdrawn. 8 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Completed 3, Terminated 3, Unknown 1, Withdrawn 1
Phase 12Completed 1, Withdrawn 1

Follow HSPPC-96: new trials by email Literature Review of HSPPC-96 trials Research Report on HSPPC-96

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
gp96, Temozolomide, radiotherapy - Glioma of Brain
Phase 2UnknownCure&Sure Biotech Co., LTD1502019-08-212020-03-12
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Pembrolizumab, HSPPC-96, Temozolomide - Glioblastoma
Phase 2TerminatedNational Cancer Institute (NCI)902017-09-212025-08-08
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
ipilimumab, HSPPC-96 - Melanoma
Phase 1 / Phase 2WithdrawnRabih Said2015-12-012016-01-25
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
HSPPC-96, bevacizumab - Recurrent Glioblastoma, Recurrent Adult Brain Tumor
Phase 2TerminatedAlliance for Clinical Trials in Oncology902013-06-192025-01-24
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
HSPPC-96 - Renal Cell Carcinoma
Phase 2TerminatedAgenus Inc.122010-01-012021-06-03
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
HSPPC-96, Temozolomide, Standard Surgical Resection - Brain and Central Nervous System Tumors
Phase 2CompletedUniversity of California, San Francisco702009-06-292021-03-24
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
HSPPC-96, Standard Surgical Resection - Brain and Central Nervous System Tumors
Phase 1 / Phase 2CompletedUniversity of California, San Francisco962005-11-182021-05-13
Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
HSPPC-96 - Non-Small-Cell Lung Carcinoma, Lung Cancer
Phase 2CompletedAgenus Inc.202003-09-012009-03-09

Conditions studied

Glioblastoma (3)  ·  Brain Neoplasms (2)  ·  Central Nervous System Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Glioma (1)  ·  Gliosarcoma (1)  ·  Lung Neoplasms (1)  ·  Melanoma (1)

Sponsors

Agenus Inc. (2)  ·  University of California, San Francisco (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Cure&Sure Biotech Co., LTD (1)  ·  National Cancer Institute (NCI) (1)  ·  Rabih Said (1)

Countries

United States (6)  ·  Canada (1)  ·  China (1)  ·  United Kingdom (1)

Top investigators

Jennifer Clarke, MD (2)  ·  Christopher G Wood, MD, FACS (1)  ·  Ian Parney, MD, PhD (1)  ·  Kevin Camphausen, M.D. (1)  ·  Louis Lacombe, MD, FRCSC (1)  ·  Orin Bloch, MD (1)  ·  Rabih Said, MD, MPH (1)  ·  Ronald P Kaufman, MD, FACS (1)

Results publications

PMID 24335700, PMID 28193626, PMID 42396282

NIH funding

P50CA097257 (1), R01CA164714 (1), U10CA031946 (1)